Scancell Holdings Plc Scancell to Present at Two Conferences
12 November 2018 - 6:00PM
RNS Non-Regulatory
TIDMSCLP
Scancell Holdings Plc
12 November 2018
12 November 2018
Scancell Holdings Plc
("Scancell" or the "Company")
Scancell to present at the LSX InvEUR$tival Showcase and
5(th) BioCentury-BayHelix China Healthcare Summit
Scancell Holdings plc, (AIM:SCLP), the developer of novel
immunotherapies for the treatment of cancer, will be presenting at
the LSX (formerly Biotech and Money) InvEUR$tival Showcase, being
held on 13 November at The Waldorf Hilton, Aldwych, London, WC2B
4DD.
Dr Cliff Holloway, Chief Executive Officer of Scancell, will be
presenting an overview of the Company and will be available to take
questions following the event. The presentation will take place at
10:45am and may be viewed live through the following web link:
https://www.lsxleaders.com/investival-showcase/stream-01
In addition, Dr Richard Goodfellow, Non-Executive Director and
former CEO of Scancell will be presenting at the 5(th)
BioCentury-BayHelix China Healthcare Summit in Shanghai. The summit
is being held on 13(th) - 14(th) November at the Jing An Shangri-La
in Shanghai, China.
Both presentations will be available through the following link:
https://www.scancell.co.uk/investors/company-docs
For Further Information:
Scancell Holdings Plc
Dr John Chiplin, Chairman +44 (0) 20 3727 1000
Dr Cliff Holloway, CEO
Panmure Gordon (UK) Limited
(Nominated Adviser and Corporate
broker)
Freddy Crossley/Emma Earl +44 (0) 20 7886 2500
FTI Consulting
Mo Noonan/Simon Conway +44 (0) 20 3727 1000
About Scancell
Scancell is developing novel immunotherapies for the treatment
of cancer based on its ImmunoBody(R) and Moditope(R) technology
platforms.
ImmunoBody(R) vaccines target dendritic cells and stimulate both
parts of the cellular immune system. They can be used as
monotherapy or in combination with checkpoint inhibitors. This
platform has the potential to enhance tumour destruction, prevent
disease recurrence and extend survival.
-- SCIB1, the lead programme, is being developed for the
treatment of melanoma. A phase 1/2 clinical trial has so far
successfully demonstrated survival data of more than five
years.
-- SCIB2 is being developed for the treatment of non-small cell
lung cancer and other solid tumours. Scancell has entered into a
clinical development partnership with Cancer Research UK for
SCIB2.
Moditope(R) represents a completely new class of potent and
selective immunotherapy agents. It stimulates the production of
killer CD4+ T cells which overcome the immune suppression induced
by tumours. allowing activated T cells to seek out and kill tumour
cells that would otherwise be hidden from the immune system.
Moditope(R) alone, or in combination with other agents, has the
potential to treat a wide variety of cancers.
-- Modi-1 is being developed for the treatment of triple
negative breast cancer, ovarian cancer and sarcomas.
For further details, please see our website:
www.scancell.co.uk
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAUAAORWBAAAUA
(END) Dow Jones Newswires
November 12, 2018 02:00 ET (07:00 GMT)
Scancell (LSE:SCLP)
Historical Stock Chart
From Apr 2024 to May 2024
Scancell (LSE:SCLP)
Historical Stock Chart
From May 2023 to May 2024